摘要
目的观察多廿烷醇治疗老年高脂血症的有效性及安全性。方法选择血脂异常老年患者34例,以多廿烷醇20 mg·d-1口服,疗程24周。用药前后检测患者空腹血糖,血脂变化,肝、肾功能等,观察多廿烷醇调脂疗效及安全性;行肱踝脉搏波传导速度(ba PWV)检查,了解其对大动脉弹性的作用;行SF-36量表检测,以评价药物对患者生活质量的影响。结果多廿烷醇治疗24周,血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、三酰甘油(TG)水平下降幅度分别为17.5%、23.6%和19.3%(P<0.05或P<0.01)。多廿烷醇治疗后,SF36值显著升高[125.32±13.93 vs.115.28±15.51(治疗前),P<0.05];用药治疗后除生理职能外,活力、生理机能、身体疼痛、总体健康、社会功能、情感职能和精神健康均有显著改善(P<0.05)。多廿烷醇治疗后ba PWV下降显著[1 527.87±232.09 vs.1 603.97±215.55(治疗前),P<0.01]。多廿烷醇治疗后血压、心率、肝功能、肾功能、肌酸激酶等均未发现显著变化(P>0.05);未有患者出现心肌激酶或丙氨酸转氨酶升高等不良事件。结论多廿烷醇治疗老年血脂异常患者,其调脂作用显著,可改善患者生活质量及大动脉弹性,安全性良好。
AIM To evaluate the efficacy and safety of policosanol in elderly patients with dyslipidemia. METHODS A total of 34 patients with dyslipidemia were enrolled in the study. All patients received policosanol 20 mg.d^-1 for 24 weeks. Lipid profile was evaluated at baseline, and after 16 and 24 weeks. Brachial-ankle artery pulse wave velocity （baPWV） was performed, and SF- 36 questionnaire were used to evaluate the patients＇ life quality before and after the treatment. Safety was assessed by recording adverse events and measuring clinical laboratory parameters. RESULTS Serum cholesterol （TC）, low density-lipoprotein cholesterol （LDL-C） and serum triglyceride （TG） were decreased by 17.5%, 23.6%, 19.3% respectively after treated with policosanol for 24 weeks （P 〈 0.05 or P 〈 0.01）. There was a significant improvement of SF-36 value （125.32 ± 13.93 vs. 115.28 ± 15.51 （baseline）, P 〈 0.05） and baPWV （1 527.87 ± 232.09 vs. 1 603.97 ± 215.55 （baseline）, P 〈 0.01） after policosanol treatment for 24 weeks. Policosanol improved SF-36 component including vitality （VT）, physical functioning （PF）, bodily pain （BP）, general health （GH）, social functioning （SF）, role emotional （RE） and mental health （MH）. No serious adverse event was reported and there were no significant changes of laboratory variables before and after the treatment. CONCLUSION Policosanol can improve lipid parameters, arterial stiffness and patient＇ s life quality, and appeare to have a good tolerability in elderly patients with dyslipidemia.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2015年第9期679-682,共4页
Chinese Journal of New Drugs and Clinical Remedies
